Health Catalyst (HCAT) Tops Q2 EPS by 4c ; Offers Guidance

Health Catalyst (NASDAQ: HCAT) reported Q2 EPS of $0.12, $0.04 better than the analyst estimate of $0.08. Revenue for the quarter came in at $75.9 million versus the consensus estimate of $74.96 million.

GUIDANCE:

Health Catalyst sees Q3 2024 revenue of $74.5-77.5 million, versus the consensus of $77.93 million.

Health Catalyst sees FY2024 revenue of $304-312 million, versus the consensus of $307.9 million.

For earnings history and earnings-related data on Health Catalyst (HCAT) click here.

You May Also Be Interested In

• Sandisk targets mid-to-high teens revenue growth through FY2030
• Ideal Power (IPWR) Tops Q2 EPS by 2c
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance